Clinical trials: Itraconazole
Healthy Participants
Assess the Drug Interactions of BBT-877 and Midazolam, Itraconazole, and Esomeprazole in Healthy Adult Subjects
Study to determine the effect of multiple-dose BBT-877 on the single-dose pharmacokinetics of midazolam, the safety and tolerability of a single dose of BBT-877 administered alone and with multiple doses of itraconazole, and the…
- Trial name
- NCT04138836
- Testing
- BBT-877, Midazolam, Itraconazole
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bridge Biotherapeutics, Inc.
Health Participants
A Study to Evaluate the Safety, Tolerability, Drug Levels and Drug Effects of Single and Multiple Doses of BMS-986209 in Healthy Participants
The purpose of this study is to investigate the safety and tolerability of BMS-986209 in healthy participants. The first-in-human study is designed in 3 parts that vary based on duration and food effect.
- Trial name
- NCT04154800
- Testing
- BMS-986209, Itraconazole, Diltiazem
- Where
- United States
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy Adult Participants
A Phase 1 Multiple Dose Trial in Healthy Adult Participants to Evaluate the Safety, Tolerability, Drug-Drug Interactions, and Pharmacokinetics of TBD11
This is a Phase 1, randomized, double-blind, placebo-controlled, multiple dose trial of TBD11 in healthy adults. It includes a dedicated open-label cohort in which TBD11 will be administered as a single dose with either a strong…
- Trial name
- NCT07883226
- Testing
- TBD11 (300 mg), Itraconazole (200 mg), Rifampicin 600mg
- Where
- South Africa
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Gates Medical Research Institute
Drug Interactions, Neoplasms
A Cross-over Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics (PK) of GSK525762 in Healthy Female Subjects of Non Child Bearing Potential
This is a Phase I, single center, two-part, randomized, open label, cross-over study. Part 1 of this study will evaluate the PK, safety, and tolerability of GSK525762 when administered alone and when co-administered following…
- Trial name
- NCT02706535
- Testing
- GSK525762 Besylate Tablets, Itraconazole 200 mg, Rifampicin 300 mg
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy Volunteers
A Study to Assess the Pharmacokinetics of AZD4831 When Administered Alone and in Combination With Itraconazole
A study to demonstrate pharmacokinetics of AZD4831 when administered alone and in combination with Itraconazole.
- Trial name
- NCT05236543
- Testing
- AZD4831, Itraconazole
- Where
- United Kingdom
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy Volunteers
A Study to Evaluate Drug-Drug Interaction of Larotinib With Itraconazole and Rifampin in Healthy Adult Participants
The purpose of this study is to characterize the effect of rifampin (Part A) and itraconazole(Part B) on the single-dose pharmacokinetics (PK) of Larotinib in healthy adult participants.
- Trial name
- Z650 (NCT05057949)
- Testing
- Larotinib, Rifampin, Itraconazole
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Healthy Volunteers
A Drug-Drug Interaction Study to Assess the Pharmacokinetics of DC-806 When Orally Administered Alone, When Coadministered With Itraconazole, and When Coadministered With Carbamazepine in Healthy Adult Participants
The primary objective of this study was to assess the effect of a cytochrome P450 3A4 (CYP3A4) inhibitor (itraconazole) and CYP3A4 inducer (carbamazepine) on the single dose pharmacokinetics (PK) of DC-806 coadministered with…
- Trial name
- NCT05994807
- Testing
- DC-806, Itraconazole, Carbamazepine
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Pharmacokinetics
Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibition and Induction on the Pharmacokinetics of CC-220 in Healthy Subjects
This is a two-part study to be conducted at a single study site in the US. Both parts of the study may be conducted in parallel.
- Trial name
- NCT02820935
- Testing
- CC-220, Rifampin, Itraconazole
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Celgene Corporation
Healthy Participants
A Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Divarasib in Healthy Participants
This is a Phase 1, open-label, two-period, fixed sequence drug-drug interaction study to evaluate the impact of multiple doses of Itraconazole on the pharmacokinetics (PK) and safety of Divarasib in healthy participants.
- Trial name
- NCT06690138
- Testing
- Divarasib, Itraconazole
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Healthy
A Study in Healthy Male Volunteers to Look at How the Test Medicine GLPG1690 is Taken up by the Body When Doses of Itraconazole and Voriconazole Are Given to Healthy Volunteers
The sponsor wants to investigate how well the test medicine is taken up by the body when given alongside two other already approved medicines. This kind of study is known as a drug-drug interaction study.
- Trial name
- NCT03515382
- Testing
- GLPG1690, Itraconazole, Voriconazole
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Lakefront Biotherapeutics NV
Healthy Volunteer
A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
Genes give your body instructions on how to make proteins. Proteins are needed to keep the body working properly. Many types of cancer are caused by changes in certain genes, making them faulty.
- Trial name
- NCT07395024
- Testing
- Setidegrasib, Fluconazole, Carbamazepine
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Global Development, Inc.
Healthy Participants
A Study to Evaluate Effect of Itraconazole on the Pharmacokinetics of Cobimetinib in Healthy Participants
This open-label, 2-period, fixed sequence, drug interaction study will investigate the effect of co-administration of itraconazole on the pharmacokinetics of cobimetinib in healthy participants.
- Trial name
- NCT01929876
- Testing
- Cobimetinib, Itraconazole
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Genentech, Inc.
Solid Tumor
A Study of AB-106 in Chinese Healthy Adult Men Evaluated the Effects of Itraconazole and Rifampicin on AB-106 PK
AB-106-C110 is China-only study, for investigating the drug interaction between AB-106 and CYP3A4 inhibitor (Itraconazole)/CYP3A4 inducer (Rifampin)（n=56）
- Trial name
- NCT05357820
- Testing
- AB-106, Itraconazole, AB-106, Rifampicin
- Where
- China
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Nuvation Bio Inc.
Healthy Volunteers
A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male Participants
The purpose of this study is to assess in healthy adult male participants the effects of itraconazole on the pharmacokinetics of venglustat and to assess the safety and tolerability of venglustat with and without coadministration…
- Trial name
- NCT06421714
- Testing
- Venglustat, Itraconazole
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Genzyme, a Sanofi Company
Healthy Volunteers
A Study to Assess Potential Drug-Drug Interactions of E2086 in Healthy Participants
The primary purpose of this study is to assess potential drug-drug interactions of E2086 when coadministered orally with Itraconazole, Carbamazepine, Midazolam, Dextromethorphan, Bupropion, or Combined Oral Contraceptives in…
- Trial name
- NCT07766369
- Testing
- E2086
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Healthy Participants
A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants
This study will be conducted to evaluate the effect of food on the single-dose pharmacokinetics and a drug-drug interaction evaluation of itraconazole and carbamazepine on INCB123667 when administered orally to healthy adult…
- Trial name
- NCT06909162
- Testing
- INCB123667, itraconazole, carbamazepine
- Where
- United States
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Healthy Volunteer
A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy Participants
This is an open label, fixed sequence, 1-way crossover drug-drug interaction (DDI) study in healthy participants.
- Trial name
- NCT06677996
- Testing
- varegacestat, Itraconazole (200 mg)
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Immunome, Inc.
Non Small Cell Lung Cancer
TGRX-326 Pharmacokinetic Drug Interaction
This is a drug-drug interaction study for TGRX-326 to evaluate the effects of CYP3A inhibitor/inducer drugs on pharmacokinetic profiles of TGRX-326, an ALK inhibitor indicated for treatment of Non-small cell lung cancer.
- Trial name
- NCT06294561
- Testing
- Itraconazole+TGRX-326, Efavirenz+TGRX-326
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Shenzhen TargetRx Co., Ltd.
Erectile Dysfunction
Drug-Drug Interaction (DDI) Study for TPN171H
The primary objective of this study was to assess the effect of rifampicin,a cytochrome P450 3A4 enzyme (CYP3A4) induction, on the pharmacokinetics (PK) of TPN171H in chinese healthy male subjects ,and assess the effect of…
- Trial name
- NCT06090123
- Testing
- TPN171H, Itraconazole, Rifampicin
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Vigonvita Life Sciences
Alzheimer's Disease
Study to Determine the Effect of Itraconazole on the Pharmacokinetics of Rilapladib (SB659032) in Healthy Volunteers
Rilapladib is a potent and selective inhibitor of lipoprotein associated phospholipase A2 (Lp-PLA2), which was previously under development for the treatment of atherosclerosis and is currently being developed for the treatment…
- Trial name
- NCT02130661
- Testing
- Rilapladib 25 mg, Rilapladib 250 mg, Itraconazole
- Volunteers
- healthy volunteers welcome
- Sponsor
- GlaxoSmithKline